PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 4, 2026Journal of Clinical Oncology1 citations

KIM-1 levels in papillary renal cell carcinoma from the CALYPSO trial.

View Full Paper
SMSara Coca MembribesFJFrancesca Jackson-SpenceCSCristina Suárez

Key Points

  • This research investigates the role of KIM-1 levels in papillary renal cell carcinoma and their correlation with tumor characteristics and treatment outcomes.
  • Analyzed serum KIM-1 concentrations in patients with papillary RCC and clear cell RCC
  • Evaluated associations between KIM-1 levels and clinicopathologic features
  • Correlated longitudinal KIM-1 changes with radiologic response and circulating tumor DNA status
  • Median KIM-1 levels in papillary RCC were significantly higher than in clear cell RCC at baseline (7835 vs 5470 pg/mL, p=0.05)
  • Higher baseline KIM-1 did not correlate with IMDC score, PD-L1, or TMB
  • Radiologic response was linked to lower baseline KIM-1 levels (3368 pg/mL in responders vs 14154 pg/mL in non-responders, p=0.025)

Abstract

557 Background: Kidney Injury Molecule-1 (KIM-1) has emerged as a promising biomarker in clear cell renal cell carcinoma (RCC), but its role in papillary RCC remains unknown. Methods: Serum KIM-1 concentrations were analyzed in patients with papillary RCC (n=32) and clear cell RCC (n=123) enrolled in a prospective randomized phase II trial evaluating durvalumab plus savolitinib (D+S) for papillary RCC. Associations between KIM-1 and clinicopathologic or molecular features were evaluated. Longitudinal changes in KIM-1 with time were correlated with radiologic response, circulating tumor DNA (ctDNA) status and molecular subgroups. Results: The median KIM1 levels for patients (n=32) with papillary RCC who received D+S was 7835 pg/mL. This was significantly higher than the clear cell RCC cohort (n=123) at baseline (5470 pg/mL, p=0.05). Other comparisons between these cohorts are shown in Table 1. In the papillary cohort, higher baseline KIM-1 levels did not correlate with the IMDC score, PD-L1 or TMB, but were lower in MET-driven tumors compared to non-MET driven (4217 vs 19834 pg/mL, p=0.05). Radiological response was associated with lower baseline KIM-1 levels (3368 vs 14154 pg/mL in non-radiological responders, p=0.025). Sequential KIM-1 results (n=19) showed a 54% decrease in radiological responders vs a 7% decrease in non-radiological responders (59% vs 11% in MET vs non-MET driven tumors). ctDNA positivity correlated with higher KIM-1 concentrations (17448 vs 5226 pg/mL in ctDNA-negative), and the combination of ctDNA positivity and elevated KIM-1 identified patients with poorer outcomes. Conclusions: KIM-1 levels are raised in papillary RCC. They correlated with tumor biology, MET status and response to treatment. Clinical trial information: NCT02819596 . Baseline serum KIM-1 levels according to clinical characteristics in papillary and clear cell RCC. Papillary RCC Clear cell RCC Baseline levels (pg/mL) 7835 5470 IMDC poor risk 40127 7998 IMDC intermediate risk 5918 6045 IMDC good risk 9789 4420 No prior nephrectomy 2282 9800 Prior nephrectomy 8705 5000 Presence of liver metastases 21321 6783 Absence of liver metastases 4791 5416

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Membribes et al. (2026) studied this question.

synapsesocial.com/papers/69a7cdaed48f933b5eeda40dhttps://doi.org/10.1200/jco.2026.44.7_suppl.557
Ask AI
Helpful
Bookmark
Share
View Full Paper